Neurology

Promising ALS treatment fails to show efficacy in Phase 3 clinical trial

The Phase 3 clinical trial evaluating the terminal complement C5 inhibitor ravulizumab for the treatment of amyotrophic lateral sclerosis (ALS) did not show significant efficacy in slowing the functional decline of participants with ALS. Despite high hopes, the study concluded that ravulizumab did not demonstrate a meaningful difference compared to...